Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2014

View Archived Issues

Takeda Pharmaceutical discloses new CH24H inhibitors

Astex Therapeutics patents novel IAP inhibitors for cancer

Novel biomarkers for Cushing's syndrome, HDR syndrome and MEN1 identified

Preclinical and early clinical data presented for prodrug of Debio-1452

Enantiomer switching of an existing drug unveils novel mechanism of action against cancer cells

GSK-2339345 proves safe in phase I trials for chronic cough

Kymab secures funding to advance clinical development of antibody therapeutics

FDA orphan status granted to diazoxide choline

ADC Therapeutics and MedImmune to advance ADCT-401 into clinic

Phase II results presented for relamorelin in chronic constipation, diabetic gastroparesis

Cellceutix reports promising findings for brilacidin in diabetic wound model

Sorrento Therapeutics discloses new antibodies for S. aureus infection

KineMed and CHDI Foundation expand Huntington's disease collaboration

Provista Diagnostics initiates clinical study of blood assay for breast cancer

Senesco Technologies completes acquisition of Fabrus

Agenix to sell its tenofovir prodrug

BioAlliance's Livatag receives FDA fast track designation

Ophthotech licenses ex-U.S. rights to Fovista to Novartis

Bioenergenix discloses novel hPASK inhibitors

Dainippon Sumitomo Pharma synthesizes new mGlu5 receptor modulators

MOR-208 receives FDA and EMA orphan drug designations

AADi in-licenses nanotechnology-based drug

Merck KGaA proposes global alliance against schistosomiasis

GSK and Genmab report topline data from pivotal head-to-head study of ofatumumab

Isis Pharmaceuticals begins phase I study of ISIS-PKK-Rx

Takeda achieves FDA approval for vedolizumab

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...